# A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

> **NCT01572727** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 416 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** BKM120 matching placebo
- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01572727
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2017-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01572727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01572727, "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01572727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*